Advances in pharmacotherapy of small cell lung cancer

Bibliography

• Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer: relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012;131:1210-19
   PubMed Web of Science ®Google Scholar
• Churg A. Lung cancer cell type and occupational exposure. In: Samet JM, editor. Epidemiology of lung cancer. Marcel Dekker, New York; 1994. p. 413-36
   Google Scholar
• Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results database. J Clin Oncol 2006;24(18S):384s
   Google Scholar
• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End-Results database. J Clin Oncol 2006;24:4539-44
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-19
   PubMed Web of Science ®Google Scholar
• Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42
   PubMedGoogle Scholar
• Goldstraw P, Crowley JJ, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification for malignant tumors. J Thorac Oncol 2007;2:706-14
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Crowley J, Van Houtte P, et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77
   PubMed Web of Science ®Google Scholar
• Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24
   PubMed Web of Science ®Google Scholar
• Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5
   PubMed Web of Science ®Google Scholar
• Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer. J Clin Oncol 2004;22:4785-93
   Google Scholar
• Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71
   PubMed Web of Science ®Google Scholar
• Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-84
   PubMed Web of Science ®Google Scholar
• Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-72
   PubMed Web of Science ®Google Scholar
• Hanna NH, Einhorn LH. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002;4:87-94
   Google Scholar
• Greco FA, Oldham RK. Clinical management of patients with small cell lung cancer. In: Greco FA, Oldham RK, Bunn PA, editors. Small cell lung cancer. Grune & Stratton, New York; 1981. p. 353-79
   Google Scholar
• Lowenbraun S, Bartolucci A, Smalley RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979;44:406-13
   PubMed Web of Science ®Google Scholar
• Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992;327:1434-41
   PubMed Web of Science ®Google Scholar
• Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-7
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-61
   PubMed Web of Science ®Google Scholar
• Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-91
   PubMed Web of Science ®Google Scholar
• Sundstrøm S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002;20:4665-72
   PubMed Web of Science ®Google Scholar
• Pujol JL, Carestia L, Duares JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8-15
   PubMed Web of Science ®Google Scholar
• Mascaux C, Paesmans M, Breghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36
   PubMed Web of Science ®Google Scholar
• Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801
   PubMed Web of Science ®Google Scholar
• Postmus PE, Berendsen HH, van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987;23:1409-11
   PubMedGoogle Scholar
• Giaccone G, Ferrati P, Donadio M, et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987;23:1697-9
   PubMedGoogle Scholar
• O’Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-7
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.J Clin Oncol. 2006;24:2038-43
   Google Scholar
• Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Cardenal F, Szxzesna A, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol 2010;21:1810-16
   PubMed Web of Science ®Google Scholar
• Kubota K, Hida T, Ishikura S, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomized phase 3 study. Lancet Oncol 2013;15:106-13
   Google Scholar
• Hermes A, Bergman B, Bremmew R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-7
   PubMed Web of Science ®Google Scholar
• Schmittel A, von Weikersthal LF, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663-7
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cislplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044-51
   PubMed Web of Science ®Google Scholar
• Fink TH, Huber RM, Heigener DF, et al. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer. J Thorac Oncol 2012;7:1432-9
   Google Scholar
• Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010;5:867-73
   Google Scholar
• Lima JP, dos Santos LV, Sasse EC, et al. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010;5:1986-93
   Google Scholar
• Thomas P, Castelnau O, Paillotin D, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 2001;19:1320-5
   PubMed Web of Science ®Google Scholar
• Lyss AP, Herndon JE, Lynch TJ, et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel. Clin Lung Cancer 2002;3:205-10
   Google Scholar
• Leyvraz S, Pampallona S, Martinelli G, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008;100:533-41
   Google Scholar
• Lorigan P, Woll PJ, O’Brien MER, et al. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 2005;97:666-74
   PubMed Web of Science ®Google Scholar
• Furuse K, Fukuoka M, Nishiwaki Y, et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. J Clin Oncol 1998;16:2126-32
   Google Scholar
• Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B trial 9732. J Clin Oncol 2005;23:3752-9
   PubMed Web of Science ®Google Scholar
• Elias A, Ibrahim J, Skarin AT, et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999;17:1175-84
   Google Scholar
• Rossi A, Garassino MC, Cinquini M, et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010;70:119-28
   PubMed Web of Science ®Google Scholar
• Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 – a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-22
   PubMed Web of Science ®Google Scholar
• Sklaros DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 1994;5:601-7
   Google Scholar
• Rossi A, DiMaio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:1692-8
   PubMed Web of Science ®Google Scholar
• Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: west Japan Thoracic Oncology Group study. Invest New Drugs 2007;25:253-8
   PubMed Web of Science ®Google Scholar
• Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small cell lung cancer. Ann Oncol 2005;16:430-6
   PubMed Web of Science ®Google Scholar
• Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol 2014;32:1262-8
   PubMed Web of Science ®Google Scholar
• Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for the treatment of refractory or relapsed small-cell lung cancer: thoracic Oncology Research Group study 0301. J Clin Oncol 2006;24:5448-53
   PubMed Web of Science ®Google Scholar
• Igawa S, Yamamoto N, Ueda S, et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007;2:741-4
   Google Scholar
• Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-603
   PubMedGoogle Scholar
• Shimokawa T, Shibuya M, Kitamura K, et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:63-9
   Google Scholar
• Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: north Japan Lung Cancer Study Group trial 0402. J Clin Oncol 2008;26:5401-6
   PubMed Web of Science ®Google Scholar
• Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-93
   PubMed Web of Science ®Google Scholar
• Jotte R, von Pawel J, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer. J Clin Oncol 2011;29(15S):453s
   Google Scholar
• Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 2008.6:315-22
   Google Scholar
• Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10
   PubMed Web of Science ®Google Scholar
• Rudin CM, Durnick S, Stawiski EW, et al. Comprehensive gneomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-16
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012;2:798-811
   PubMed Web of Science ®Google Scholar
• Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012;109:17034-9
   PubMed Web of Science ®Google Scholar
• Lassen UN, Hirsh FR, Osterlind K, et al. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer 1998;20:151-60
   PubMed Web of Science ®Google Scholar
• Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32
   PubMed Web of Science ®Google Scholar
• Spigel DR, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-22
   PubMed Web of Science ®Google Scholar
• Pujol JL, Lavole A, Quoix E, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: IFCT-0802 trial. J Clin Oncol 2014;32(15S):478s
   Google Scholar
• Allen JW, Moon J, Gadgeel SM, et al. SWOG 0802: a randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer. J Clin Oncol 2012;30(15S):453s
   Google Scholar
• Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an Intergroup Study FNCLCC cleo04-IFCT 00-01. J Clin Oncol 2007;25:3945-51
   PubMed Web of Science ®Google Scholar
• Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo controlled trial. J Natl Cancer Inst 2009;101:1049-57
   PubMedGoogle Scholar
• Schneider BJ, Gadgeel SM, Ramnath N, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 2011;6:1117-20
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 2013;79:137-42
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer. J Thorac Oncol 2010;5:1835-40
   PubMed Web of Science ®Google Scholar
• Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278-84
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 2010;5:1279-84
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Kalemkerian GP, Ramnath N, et al. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit-positive, extensive-stage small-cell lung cancer. Clin Lung Cancer 2010;11:223-7
   PubMed Web of Science ®Google Scholar
• Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (STI571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;6.1811-6
   Google Scholar
• Miller AA, Pang H, Hodgson L, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 2010;5:380-4
   PubMed Web of Science ®Google Scholar
• Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006;52:93-7
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-41
   PubMed Web of Science ®Google Scholar
• Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapsed small-cell lung cancer. Ann Oncol 2004;15:1187-93
   PubMed Web of Science ®Google Scholar
• Belani CP, Dahlberg SE, Rudin CM, et al. Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib or cixitumumab for patients with extensive-stage small cell lung cancer (ECOG 1508). J Clin Oncol 2013;31(15S):460s
   Google Scholar
• Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9
   PubMed Web of Science ®Google Scholar
• Rigas JR, Denham CA, Rinaldi DA, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor, BAY12-9566, as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 2003;22:628
   Google Scholar
• Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol 2008;26:870-6
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011;74:481-5
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012;18:3163-9
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Qi Y, Koczywas M, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011;6:1757-60
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP, Jiroutek M, Ettinger DS, et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group study. Cancer 1998;83:1102-8
   PubMedGoogle Scholar
• Schneider BJ, Worden FP, Gadgeel SM, et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 2009;27:571-8
   PubMed Web of Science ®Google Scholar
• Otterson GA, Hodgson L, Pang H, et al. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010;5:1644-8
   PubMed Web of Science ®Google Scholar
• Melichar B, Adenis A, Havel L, et al. Phase I/II study of investigational Aurora A kinase inhibitor MLN8237 (alisertib): updates ph II results in patients with small cell lung cancer, non-SCLC, breast cancer, head and neck squamous cell carcinoma, and gastroesophageal cancer. J Clin Oncol 2013;31(15S):33s
   Google Scholar
• Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971B; Silva Study). J Clin Oncol 2005;23:6854-64
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res 2011;17:888-95
   Web of Science ®Google Scholar
• Molina JR, Mandrekar SJ, Dy GK, et al. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study. J Clin Oncol 2013;31(15S):460s
   Google Scholar